Management of Eczema by Specific Probiotic Strains (BAMBOO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01230190|
Recruitment Status : Withdrawn (Because of safety issues/support concerning the multispecies probiotic mixture)
First Posted : October 29, 2010
Last Update Posted : January 12, 2016
|Condition or disease||Intervention/treatment||Phase|
|Eczema Atopic Dermatitis||Dietary Supplement: Ecologic ® Panda II Dietary Supplement: placebo||Phase 3|
Atopic dermatitis (AD) is a highly prevalent chronic, itching, inflammatory skin disease that often presents in infancy. The disease can be the first manifestation of the so-called atopic march, the natural progression of allergic disorders, with subsequent development of asthma and allergic rhinitis. Approximately 40% of the children with AD will develop asthma later in childhood.
Currently, topical corticosteroids are the mainstay treatment of atopic dermatitis; however, relapses are common and parents often fear possible side-effects, leading to non-compliance. There is increasing evidence that the intestinal microbiota plays an important role in the development of allergic diseases. Modulation of the intestinal microbiota with probiotics, living micro-organisms with immunomodulatory effects, could possibly offer a new way of treatment of allergic disease.
Clinical trials investigating the preventive as well as therapeutic effect of probiotics on atopic dermatitis show inconsistent results. Systematic (Cochrane) reviews of all clinical trials (about treatment of AD by use of probiotics) concluded that the probiotic strains studied to date are not an effective treatment for AD; however, there is great heterogeneity between studies since many different probiotic strains are used. Because of the known strain specific capacity in immunomodulatory effects, some strains might have a greater effect than others.
Better results can possibly be achieved by using a selected, (in laboratory setting) proven modulatory multispecies probiotic mixture, containing 6 different strains.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Beyond Conventional Treatment of Atopic Eczema in Infants: Management By Specific prObiOtic Strains|
|Study Start Date :||March 2011|
|Estimated Primary Completion Date :||July 2011|
|Estimated Study Completion Date :||July 2011|
Active Comparator: Probiotic mixture
participants daily ingest a selected probiotic mixture for a period of 3 months
Dietary Supplement: Ecologic ® Panda II
Probiotic strains: 3 Bifidobacteria, 3 Lactococci, 1*10^9 Colony Forming Units/g.
Composition: rice starch, maltodextrins, bacterial strains and mix of minerals.
Other Name: multispecies probiotic mixture
Placebo Comparator: Placebo mixture
controls daily ingest a placebo mixture for a period of 3 months.
Dietary Supplement: placebo
rice starch, maltodextrins, and mix of minerals. The placebo mixture is similar in aspect, consistency and taste as Ecologic ® Panda II (intervention).
Other Name: placebo mixture
- decrease in severity of atopic dermatitis [ Time Frame: 6 months ]
The primary outcome will be measured by change in the severity of AD by using the SCORAD score.
Other outcomes: subjective (parental) change in eczema severity, change in amount of and type of topical steroid use, quality of life during and after intervention (measured by ITQOL questionnaire), amount of respiratory tract infections, use of antibiotics, use of primary care medicine (general practitioner).
All used probiotic strains contain the QPS status. (serious) adverse events will be recorded systematically.
- Effects on infant gut microbiota [ Time Frame: 6 months ]Analyses will be done by molecular microbiological techniques on feces samples (that will be collected at baseline, and after 1,3 and 6 months after enrollment.
- Effects on the immature immune system [ Time Frame: 6 months ]These effects will be measured by analyzing serum IgE and different (Th1/Th2) cytokines and chemokines
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01230190
|St. Antonius Ziekenhuis|
|Nieuwegein, Utrecht, Netherlands, 3430 EM|
|Principal Investigator:||Arine M Vlieger, MD, PhD||St. Antonius Ziekenhuis Nieuwegein, The Netherlands|